Form 4: RA Capital Director Receives SpyGlass Pharma Options

Dr. Zachary Scheiner, a director representing RA Capital Management at SpyGlass Pharma, was granted 27,400 stock options at an exercise price of $16, vesting monthly over three years.

Summary

• RA Capital Management, L.P., along with related entities and individuals (Peter Kolchinsky, Rajeev M. Shah), filed a Form 4 regarding a stock option grant.
• Dr. Zachary Scheiner, a Principal of RA Capital Management, L.P. and an Outside Director of SpyGlass Pharma, Inc. (SGP), was granted 27,400 stock options.
• The stock options have an exercise price of $16 per share.
• The options were granted on February 5, 2026, and become exercisable on the same date, with an expiration date of February 5, 2036.
• The options vest monthly, with one thirty-sixth (1/36th) of the shares vesting each month following the grant date, contingent on Dr. Scheiner's continued service as an Outside Director.
• Dr. Scheiner holds the option for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P.
• Any net cash or stock received upon exercise of the option by Dr. Scheiner is obligated to be turned over to RA Capital Management, L.P., offsetting advisory fees owed by the funds.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents standard director compensation and fosters alignment between a key director and shareholder interests, without introducing significant new financial or operational information.

Positives

• The grant aligns the interests of a key director, Dr. Zachary Scheiner, with the long-term performance of SpyGlass Pharma, Inc. through equity ownership.
• The vesting schedule encourages Dr. Scheiner's continued commitment and service to the company over a three-year period.

Future Outlook

The vesting schedule indicates a commitment for Dr. Scheiner to continue serving as an Outside Director for SpyGlass Pharma, Inc. for at least three years to fully realize the benefit of the option grant.

Management Comments

• Dr. Zachary Scheiner, a Principal of RA Capital Management, serves on the Issuer's board of directors.
• RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund III, L.P., Dr. Peter Kolchinsky, and Mr. Rajeev Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.
• Dr. Scheiner holds the option for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P., and is obligated to turn over any net cash or stock received upon exercise to RA Capital Management, L.P. to offset advisory fees.

Industry Context

StockSavvy.ai notes that granting stock options to non-employee directors is a standard practice in the biotechnology and pharmaceutical industries. This compensation structure is designed to align the interests of directors with those of shareholders, encouraging long-term strategic oversight and value creation.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a common practice across the biotechnology and pharmaceutical sectors, aligning director incentives with long-term shareholder value. For example, similar compensation structures are observed at companies like Moderna, BioNTech, and Gilead Sciences for their independent directors, typically involving multi-year vesting schedules to ensure sustained commitment.
• The exercise price of $16 and the 10-year expiration period are within typical ranges for director option grants in the industry, reflecting a long-term incentive structure.

Corporate Governance

Related Party Transactions

• Dr. Zachary Scheiner, a Principal of RA Capital Management, L.P., received stock options from SpyGlass Pharma, Inc. while also serving as an Outside Director.
• Dr. Scheiner holds these options for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P., both managed by RA Capital Management, L.P.
• Any net proceeds from the exercise of these options will be turned over to RA Capital Management, L.P. to offset advisory fees owed by the aforementioned funds, indicating a direct financial link between the director's compensation and the investment manager's fees.

Stakeholder Impact

• Shareholders: The grant aligns the interests of a director representing a significant investor (RA Capital) with the long-term value creation for all shareholders.
• Employees: No direct impact mentioned for general employees.
• RA Capital Funds: The arrangement ensures that the funds indirectly benefit from the director's equity compensation, potentially reducing advisory fees.

Next Steps

• Dr. Scheiner's continued service as an Outside Director is required for the monthly vesting of the stock options.
• The options can be exercised at any time after vesting, up to the expiration date of February 5, 2036.

Key Dates

Recommendation

This Form 4 reports a standard compensation grant to a non-employee director, which is a routine governance practice. It does not introduce new material information that would alter the fundamental investment thesis for SpyGlass Pharma, Inc., thus a 'hold' recommendation is maintained.

Keywords

SpyGlass Pharma, SGP, RA Capital Management, Stock Options, Director Compensation, Insider Transaction, Equity Incentive Plan, Beneficial Ownership